Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cardiff Oncology Inc
XE7CCurrent price
3.26 EUR
-0.096 EUR (-2.84%)
Last closed
3.81 USD
Company
www.cardiffoncology.com
ISIN
US14147L1089
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
149 191 472 USD
Yield for 12 month
+275.23 %
1Y
3Y
5Y
10Y
15Y
XE7C
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Address: 11055 Flintkote Avenue, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
9.67 USDP/E ratio
–Dividend Yield
–Current Year
+488 000 USD
Last Year
+386 000 USD
Current Quarter
+163 000 USD
Last Quarter
+205 000 USD
Current Year
+90 000 USD
Last Year
+186 000 USD
Current Quarter
+58 000 USD
Last Quarter
+103 000 USD
Key Figures XE7C
1 year
3 years
5 years
10 years
EBITDA
-44 213 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-34.12 %
PEG Ratio
–
Return On Equity TTM
-58.8 %
Wall Street Target Price
9.67 USD
Revenue TTM
665 000 USD
Book Value
1.15 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
50.9 %
Dividend Yield
–
Gross Profit TTM
-26 721 000 USD
Earnings per share
-0.92 USD
Diluted Eps TTM
-0.92 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics XE7C
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History XE7C
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:6
Payout Ratio
–
Last Split Date
20.02.2019
Dividend Date
20.02.2019
Stock Valuation XE7C
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
136.4144
Price Sales TTM
224.3481
Enterprise Value EBITDA
-3.6608
Price Book MRQ
2.8478
Financials XE7C
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators XE7C
For 52 weeks
0.94 USD
6.42 USD
50 Day MA
2.61 USD
Shares Short Prior Month
6 826 675
200 Day MA
2.99 USD
Short Ratio
13.38
Shares Short
7 315 126
Short Percent
16.16 %
BeatStart